Innovating Works

KRAFFT

Activa
BRIGHT: Treat severe cases of infection at COV with XAV 19 XENOTHERA tramitó un H2020: H2020-EIC-SMEInst-2018-2020 Since 2014 XENOTHERA has developed a platform for producing Glyco-Humanized Polyclonal Antibodies (GH-pAb) with high efficiency and optimize...
2020-07-27 - 2022-12-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.